{
  "meta": {
    "title": "Rheumatoid_Arthritis",
    "url": "https://brainandscalpel.vercel.app/rheumatoid-arthritis-cc0b96c5.html",
    "scrapedAt": "2025-11-30T11:13:20.702Z"
  },
  "questions": [
    {
      "id": 1,
      "choices": [
        {
          "id": 1,
          "text": "<p><span style=\"font-size:12.0pt;\">Dermatomyositis</span></p>"
        },
        {
          "id": 2,
          "text": "<p><span style=\"font-size:12.0pt;\">Systemic lupus erythematosus</span></p>"
        },
        {
          "id": 3,
          "text": "<p><span style=\"font-size:12.0pt;\">Rheumatoid arthritis</span></p>"
        },
        {
          "id": 4,
          "text": "<p><span style=\"font-size:12.0pt;\">Polymyalgia rheumatica</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 54-year-old patient presents with an 8-week history of pain and stiffness in her shoulders and wrists. The symptoms improve over the day. On examination, there was synovitis of both wrists and proximal muscle wasting. Her ESR was 40 mm/hr.<br>What is the likely diagnosis?</span></p>",
      "unique_key": "DT1197733",
      "question_audio": null,
      "question_video": null,
      "map_id": 1197733,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>In a <strong>middle-aged female</strong>, arthritis of the shoulders and wrists along with synovitis is highly suggestive of acute <strong>Rheumatoid Arthritis</strong>.</li>\n<li><strong>Morning stiffness</strong> improving over the day is another <strong>hallmark of RA.</strong></li>\n<li>The presence of synovitis and joint inflammation is critical for diagnosis, and the <strong>ESR elevation</strong> supports an <strong>inflammatory aetiology.</strong></li>\n<li><strong>Polymyalgia Rheumatica</strong> mainly presents with <strong>synovitis of proximal large joints</strong>. It is not associated with wasting or weakness. <strong>(Option D ruled out)</strong></li>\n<li><strong>Dermatomyositis</strong> presents with <strong>non-specific arthralgias</strong>, but not arthritis <strong>(Option A ruled out)</strong></li>\n<li><strong>SLE</strong> can present with <strong>inflammatory arthritis</strong>, which is typically non-erosive and lacks the features of synovitis and effusions as seen with RA. <strong>(Option B ruled out)</strong></li>\n</ul>",
      "correct_choice_id": 3,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 2,
      "choices": [
        {
          "id": 11,
          "text": "<p><span style=\"font-size:12.0pt;\">Advanced age</span></p>"
        },
        {
          "id": 12,
          "text": "<p><span style=\"font-size:12.0pt;\">Duration of morning stiffness</span></p>"
        },
        {
          "id": 13,
          "text": "<p><span style=\"font-size:12.0pt;\">ESR 55 mm/Hr</span></p>"
        },
        {
          "id": 14,
          "text": "<p><span style=\"font-size:12.0pt;\">Rheumatoid factor titre 1:80 mg/L</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 67-year-old woman is referred by her GP for a six-month history of acute onset, progressively worsening shoulder pain, occurring bilaterally and associated with morning stiffness lasting approximately one hour. The GP's letter states that basic bloods demonstrated: Westergren ESR 55 mm/Hr (0 - 30), CRP 1mg/L(<10), Rheumatoid factor titre 1:80(<1:40). Which one of the following increases the probability of a diagnosis other than polymyalgia rheumatica?</span></p>",
      "unique_key": "DT1186773",
      "question_audio": null,
      "question_video": null,
      "map_id": 1186773,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation</strong>:</p>\n<ul>\n<li>The presence of a <strong>positive rheumatoid factor (RF)</strong> increases the probability of an alternative diagnosis, particularly <strong>rheumatoid arthritis</strong> (RA), rather than polymyalgia rheumatica (PMR).</li>\n<li>RA typically involves the <strong>distal joints</strong>, whereas PMR usually involves <strong>proximal muscle groups</strong> like the shoulders and hips.</li>\n<li>Although PMR can present with elevated inflammatory markers (e.g., ESR, CRP) and morning stiffness in elderly individuals, <strong>RF positivity</strong> suggests another autoimmune rheumatologic condition, especially <strong>seropositive RA</strong>.</li>\n</ul>\n<p>Features of PMR include:</p>\n<ul>\n<li>Age &gt;50 years, duration &gt;2 weeks <strong>(Option A)</strong></li>\n<li>Bilateral shoulder or pelvic girdle aching, or both</li>\n<li>Morning stiffness duration of &gt;45 min <strong>(Option B)</strong></li>\n<li>Evidence of an acute-phase response, ESR is frequently <strong>elevated in PMR (Option C)</strong></li>\n<li>Exclusion of other rheumatological illnesses as a cause for the musculoskeletal symptoms.</li>\n</ul>",
      "correct_choice_id": 14,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3,
      "choices": [
        {
          "id": 21,
          "text": "<p><span style=\"font-size:12.0pt;\"><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; min-width:150px; max-width:150px; \"src=\"https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/202312079eea9479-1964-4830-bd63-7a456b939369.jpg\"></span></p>"
        },
        {
          "id": 22,
          "text": "<p><span style=\"font-size:12.0pt;\"><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; min-width:150px; max-width:150px; \"src=\"https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/202312079ef0e8ef-eea2-4477-b970-bd56aff8b3ad.jpg\"></span></p>"
        },
        {
          "id": 23,
          "text": "<p><span style=\"font-size:12.0pt;\"><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; min-width:150px; max-width:150px; \"src=\"https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/2023120734808605-4eec-43d6-a36e-2fbf9fce0189.jpg\"></span></p>"
        },
        {
          "id": 24,
          "text": "<p><span style=\"font-size:12.0pt;\"><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; min-width:150px; max-width:150px; \"src=\"https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/2023120723c86d56-b230-4ea3-a5e8-57bf87350c6d.jpg\"></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 70-year-old female with long long-standing history of untreated RA comes to your OP with deformities. Which among the following represents Boutonniere deformity?</span></p>",
      "unique_key": "DT1220911",
      "question_audio": null,
      "question_video": null,
      "map_id": 1220911,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>All 4 of the figures represent the joint deformities that we come across in Rheumatoid arthritis</p>\n<p>A. The first figure shows <strong>flexion of the DIP</strong> and <strong>hyperextension of the PIP</strong>, known as <strong>Swan Neck deformity.</strong></p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; min-width:150px; max-width:150px; \"src=\"https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/202312079eea9479-1964-4830-bd63-7a456b939369.jpg\">\n<p>B. The second figure shows the <strong>prominence of the ulnar styloid</strong> due to <strong>destruction of the ulnar collateral ligament</strong>. This causes <strong>floating of the ulnar head</strong>, causing<strong> \" Piano-Key\" deformity.</strong></p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; min-width:150px; max-width:150px; \"src=\"https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/202312079ef0e8ef-eea2-4477-b970-bd56aff8b3ad.jpg\">\n<p>C. The third figure shows <strong>subluxation of the first MCP</strong> with <strong>hyperextension of the thumb</strong>, called the <strong>Z line deformity</strong>.</p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; min-width:150px; max-width:150px; \"src=\"https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/2023120734808605-4eec-43d6-a36e-2fbf9fce0189.jpg\">\n<p>D. The fourth figure shows the <strong>Boutonniere deformity</strong>, characterised by <strong>flexion of the PIP and extension at DIP.</strong></p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; min-width:150px; max-width:150px; \"src=\"https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/2023120723c86d56-b230-4ea3-a5e8-57bf87350c6d.jpg\">",
      "correct_choice_id": 24,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 4,
      "choices": [
        {
          "id": 31,
          "text": "<p><span style=\"font-size:12.0pt;\">1, 2 and 3</span></p>"
        },
        {
          "id": 32,
          "text": "<p><span style=\"font-size:12.0pt;\">4 and 5</span></p>"
        },
        {
          "id": 33,
          "text": "<p><span style=\"font-size:12.0pt;\">3</span></p>"
        },
        {
          "id": 34,
          "text": "<p><span style=\"font-size:12.0pt;\">5 and 6</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 70-year-old male with a history of long-standing arthritis of small and large joints that are symmetrical presents with the following lesion in the elbow.<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20231207bada2f2b-8fdc-4a57-8c53-2240b6a1c6d9.jpg\"><br>Which of the following statements is false?<br>1. Such nodules could be found in the lung, pleura, pericardium, periosteum, etc., in patients with RA.<br>2. In RA, the nodules are more commonly seen in those with high disease activity.<br>3. Rheumatoid nodules are tender on palpation.<br>4. Accelerated growth of the nodules can take place in 10% of patients taking Methotrexate in patients with RA.<br>5. They have a strong association with smoking.<br>6. Arthritis and nodules can occur in RA, SLE, Gout and Acute Rheumatic Fever.</span></p>",
      "unique_key": "DT1220913",
      "question_audio": null,
      "question_video": null,
      "map_id": 1220913,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>The figure shows subcutaneous nodules in the extensor aspect of the forearm in a patient with arthritis. On seeing the joints of the hands, he is most likely suffering from RA.</li>\n<li>So the question is basically about Rheumatoid Nodules.</li>\n<li>Rheumatoid nodules are <strong>painless nodules</strong>seen in areas where the skeleton is subjected to repeated trauma, like the forearm, Achilles tendon, etc.</li>\n<li><strong>Rheumatoid nodules are seen in patients with high disease activity</strong>, <strong>cigarette smoking</strong> and RA positivity. <strong>(Statements 2 and 5)</strong></li>\n<li>The nodules can be seen in the <strong>lung, pleura, pericardium and periosteum</strong> <strong>(Statement 1)</strong></li>\n<li>In up to <strong>10% of patients</strong>, treatment with <strong>Methotrexate</strong> can lead to an <strong>unexplained increase in the size of the nodules. (Statement 4)</strong></li>\n<li><strong>Other rheumatological conditions that can be associated with arthritis and nodules are SLE, Acute Rheumatic Fever, and Chronic Gout. (Statement 6)</strong></li>\n<li>Upon histological examination, they have a necrotic centre with a palisading corona of fibroblasts.</li>\n</ul>",
      "correct_choice_id": 33,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5,
      "choices": [
        {
          "id": 41,
          "text": "<p><span style=\"font-size:12.0pt;\">1 and 4</span></p>"
        },
        {
          "id": 42,
          "text": "<p><span style=\"font-size:12.0pt;\">1, 2 and 3</span></p>"
        },
        {
          "id": 43,
          "text": "<p><span style=\"font-size:12.0pt;\">2, 3 and 4</span></p>"
        },
        {
          "id": 44,
          "text": "<p><span style=\"font-size:12.0pt;\">1 and 5</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Identify the false statements.<br>1. The ILD in RA has a worse prognosis than Idiopathic Pulmonary Fibrosis.<br>2. Caplan's syndrome is pulmonary nodules and Pneumoconiosis following Silica exposure.<br>3. Mitral regurgitation is seen more in patients with RA than in the general population.<br>4. The most common cause of mortality in RA is infections.<br>5. The incidence of osteoporosis is higher in patients with RA than in the general population.</span></p>",
      "unique_key": "DT1220915",
      "question_audio": null,
      "question_video": null,
      "map_id": 1220915,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation</strong>:</p>\n<ul>\n<li>This question deals with the <strong>extra-articular manifestations in RA.</strong></li>\n<li>Pulmonary manifestations of RA include pleuritis (most common), ILD and nodules.</li>\n<li>The <strong>ILD</strong> in <strong>RA</strong> indicates a worse prognosis, but in general, the <strong>prognosis is better than Idiopathic pulmonary fibrosis. </strong></li>\n<li><strong>Caplan's Syndrome is pulmonary nodules with pneumoconiosis seen after exposure to Silica</strong>.<strong> (Statement 2)</strong></li>\n<li>Cardiac manifestations include pericarditis and cardiomyopathy. They have a <strong>higher incidence of MR than the general population. (Statement 3)</strong></li>\n<li>The <strong>most common cause of mortality</strong> in RA is <strong>cardiovascular disease and not infections. </strong></li>\n<li>The patients with RA are at a higher risk for developing coronary artery disease independent of conventional risk factors.</li>\n<li>Patients with RA are also at a <strong>higher risk of osteoporosis</strong> than the general population due to spillage of the inflammation spreading to the surrounding bone. <strong>(Statement 5)</strong></li>\n</ul>",
      "correct_choice_id": 41,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6,
      "choices": [
        {
          "id": 51,
          "text": "<p><span style=\"font-size:12.0pt;\">Anaemia chronic disease</span></p>"
        },
        {
          "id": 52,
          "text": "<p><span style=\"font-size:12.0pt;\">Upper GI bleed</span></p>"
        },
        {
          "id": 53,
          "text": "<p><span style=\"font-size:12.0pt;\">Felty's syndrome</span></p>"
        },
        {
          "id": 54,
          "text": "<p><span style=\"font-size:12.0pt;\">Folate deficiency</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 51-year-old woman with long-standing rheumatoid arthritis. She presents with increasing malaise. Investigations showed:<br>Hb 7.5 g/dl<br>Neutrophil count 1.2 x 10^9/L<br>platelet count 90 x 10^9/L<br>Her ESR was 120 mm/hr and CRP 145 mg/dl.<br>On examination, she was pale and had palpable splenomegaly.<br>The most likely cause of her haematologic abnormalities is:</span></p>",
      "unique_key": "DT1197693",
      "question_audio": null,
      "question_video": null,
      "map_id": 1197693,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation</strong>:</p>\n<ul>\n<li><strong>Felty's syndrome</strong> is characterised by a classic clinical triad:\n<ul>\n<li><strong>Neutropenia</strong>,</li>\n<li><strong>Splenomegaly</strong>, and</li>\n<li><strong>Rheumatoid arthritis (RA)</strong>, typically nodular and longstanding.</li>\n</ul>\n</li>\n<li>This syndrome occurs in &lt;1% of patients with RA, usually in those with <strong>longstanding, severe, and seropositive RA</strong>.</li>\n<li>The pathogenesis is likely immune-mediated, and early aggressive treatment of RA has reduced its incidence.</li>\n<li>The combination of <strong>anaemia, neutropenia, thrombocytopenia, high inflammatory markers (ESR and CRP)</strong>, and <strong>splenomegaly</strong> in a patient with RA is characteristic of <strong>Felty's syndrome</strong>.</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Anaemia of chronic disease (Option A):</strong> Would explain anaemia but <strong>not</strong> the neutropenia, thrombocytopenia, or splenomegaly.</p>\n<p><strong>Upper GI bleed (Option B):</strong> GI bleeding can cause anaemia, but typically not neutropenia or splenomegaly.</p>\n<p><strong>Folate deficiency (Option D) </strong>can lead to anaemia, but would <strong>not</strong> cause neutropenia or splenomegaly in this clinical context.</p>",
      "correct_choice_id": 53,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 7,
      "choices": [
        {
          "id": 61,
          "text": "<p><span style=\"font-size:12.0pt;\">1, 2, 3</span></p>"
        },
        {
          "id": 62,
          "text": "<p><span style=\"font-size:12.0pt;\">2, 3, 4</span></p>"
        },
        {
          "id": 63,
          "text": "<p><span style=\"font-size:12.0pt;\">2, 3</span></p>"
        },
        {
          "id": 64,
          "text": "<p><span style=\"font-size:12.0pt;\">1, 3, 4</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 34-year-old woman with newly diagnosed rheumatoid arthritis enquires about risk factors.<br>1- Pneumococcal infection<br>2- HLA-DR4<br>3- Porphyromonas Gingivalis<br>4- Smoking<br>Which one of the following is a risk factor for rheumatoid arthritis?</span></p>",
      "unique_key": "DT1197690",
      "question_audio": null,
      "question_video": null,
      "map_id": 1197690,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation</strong>:</p>\n<p>Risk factors for rheumatoid arthritis are:</p>\n<ul>\n<li><strong>Genetic predisposition: </strong>particularly<strong> HLA-DR4 </strong>and<strong> HLA-DR1 alleles</strong></li>\n<li>EBV</li>\n<li>Oral microbiome, specifically <strong>Porphyromonas gingivalis</strong></li>\n<li><strong>Smoking (induces RF production)</strong></li>\n<li>Obesity</li>\n<li>Pregnancy and OCP are protective.</li>\n</ul>\n<p><strong>Pneumococcal infection </strong>is not a recognised risk factor for RA. It may occur as a complication due to immunosuppression, but it does <strong>not</strong> contribute to pathogenesis.</p>",
      "correct_choice_id": 62,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 8,
      "choices": [
        {
          "id": 71,
          "text": "<p><span style=\"font-size:12.0pt;\">IFN gamma</span></p>"
        },
        {
          "id": 72,
          "text": "<p><span style=\"font-size:12.0pt;\">Interleukin 8</span></p>"
        },
        {
          "id": 73,
          "text": "<p><span style=\"font-size:12.0pt;\">TNF alpha</span></p>"
        },
        {
          "id": 74,
          "text": "<p><span style=\"font-size:12.0pt;\">Endotoxin</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 58-year-old lady has polyarthritis due to Rheumatoid Arthritis.<br>Which one of the following molecules plays a central role in its pathogenesis?</span></p>",
      "unique_key": "DT1197675",
      "question_audio": null,
      "question_video": null,
      "map_id": 1197675,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation</strong>:</p>\n<ul>\n<li>Rheumatoid arthritis (RA) is a <strong>macrophage-driven chronic inflammatory disorder</strong>.</li>\n<li>Macrophages in RA secrete a range of proinflammatory cytokines that sustain synovial inflammation.</li>\n<li>Among these, <strong>Tumour Necrosis Factor-alpha (TNF-&alpha;)</strong> is the most critical cytokine mediating cartilage destruction and joint damage.</li>\n<li>TNF-&alpha; <strong>stimulates synovial fibroblasts</strong> and promotes the <strong>release of matrix metalloproteinases.</strong></li>\n<li>It also drives recruitment and activation of other immune cells, amplifying inflammation.</li>\n<li>TNF-&alpha; inhibitors (like infliximab, adalimumab) have shown major clinical benefits in RA.</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>IFN gamma (Option A):</strong> This Th1 cytokine is involved in cell-mediated immunity but plays a minor role in RA compared to TNF-&alpha;.</p>\n<p><strong>Interleukin 8 (Option B):</strong> IL-8 is a neutrophil chemoattractant and has secondary involvement in inflammation, but is not central to RA pathogenesis.</p>\n<p><strong>Endotoxin (Option D):</strong> Endotoxins are components of gram-negative bacteria and are unrelated to the autoimmune aetiology of RA.</p>",
      "correct_choice_id": 73,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 9,
      "choices": [
        {
          "id": 81,
          "text": "<p><span style=\"font-size:12.0pt;\">Macrophages</span></p>"
        },
        {
          "id": 82,
          "text": "<p><span style=\"font-size:12.0pt;\">Osteoclasts</span></p>"
        },
        {
          "id": 83,
          "text": "<p><span style=\"font-size:12.0pt;\">CD4 T cells</span></p>"
        },
        {
          "id": 84,
          "text": "<p><span style=\"font-size:12.0pt;\">B cells</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which cell is primarily involved in causing structural damage to joints in RA?</span></p>",
      "unique_key": "DT1220921",
      "question_audio": null,
      "question_video": null,
      "map_id": 1220921,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<ul>\n<li><strong>Osteoclasts</strong> are the cells that are ultimately responsible for the <strong>structural damage in RA.</strong></li>\n<li>The <strong>chief pathology</strong> of RA is not only <strong>bone destruction</strong>, but also <strong>decreased bone formation.</strong><br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20231207be16f7b2-bf61-4592-a797-5624aab50d84.jpg\"></li>\n<li>The first cells that are activated are <strong>CD4+ T cells. (Option C ruled out)</strong></li>\n<li><strong>Macrophages</strong> are the <strong>chief inflammatory cells</strong> But the bone damage is mediated by activated osteoclasts.<strong> (Option A ruled out)</strong></li>\n<li><strong>B cells </strong>contribute via <strong>autoantibody production</strong> (<strong>like RF and anti-CCP</strong>), <strong>but do not mediate structural joint damage. (Option D ruled out)</strong></li>\n<li>Bone erosions: The damage is typically located at the regions where the synovium is inserted into the periosteal surface at the edge of bone, at the rim of the articular cartilage. This also explains the development of bone erosions at the radial aspect of the MCP.</li>\n<li>Juxta-articular osteopenia is another pathology that is seen in the adjacent bone due to inflammation of the marrow. It results in substantial thinning of bone trabeculae.</li>\n<li><strong>TNF&alpha;</strong> <strong>inhibits bone formation</strong> by inhibiting osteoblasts.</li>\n</ul>",
      "correct_choice_id": 82,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 10,
      "choices": [
        {
          "id": 91,
          "text": "<p><span style=\"font-size:12.0pt;\">IgA antibody</span></p>"
        },
        {
          "id": 92,
          "text": "<p><span style=\"font-size:12.0pt;\">IgM antibody</span></p>"
        },
        {
          "id": 93,
          "text": "<p><span style=\"font-size:12.0pt;\">IgE antibody</span></p>"
        },
        {
          "id": 94,
          "text": "<p><span style=\"font-size:12.0pt;\">IgD antibody</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 33-year-old lady presents with stiffness, pain and swelling of her hands and wrists. Investigations reveal a normocytic, normochromic anaemia, elevated ESR and CRP. What antibody would you use if you wanted to do A test for detecting RA factor?</span></p>",
      "unique_key": "DT1197679",
      "question_audio": null,
      "question_video": null,
      "map_id": 1197679,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation</strong>:</p>\n<ul>\n<li>Rheumatoid factor (RF) is an autoantibody directed against the Fc portion of IgG.<br /> It exists in several isotypes: <strong>IgM</strong>, IgG, and IgA.</li>\n<li>Among these, <strong>IgM-RF</strong> is the <strong>most commonly measured isotype</strong> in routine diagnostic tests for RA.</li>\n<li><strong>IgM-RF</strong> is present in approximately 75% of RA patients.</li>\n<li>However, its <strong>sensitivity is limited</strong>, and it can be negative in early disease.</li>\n<li>RF can also be <strong>false positive</strong> in other connective tissue diseases (e.g., Sjogren's syndrome, SLE), chronic infections (e.g., hepatitis B, C, subacute bacterial endocarditis), and even in 1-5% of healthy individuals.</li>\n<li><strong>Anti-CCP antibodies</strong> are more specific for RA (&asymp;95%) and associated with worse prognosis, but they are not part of the RF assay.</li>\n<li><strong>IgA-RF</strong> can be found in RA, but is <strong>not the primary isotype</strong> used in commercial RF testing <strong>(Option A ruled out)</strong></li>\n<li><strong>IgE antibody </strong>is not involved in RF detection. IgE is associated with allergic responses. <strong>(Option C ruled out).</strong></li>\n<li><strong>IgD </strong>is not relevant to RF testing or RA pathogenesis.<strong> (Option D ruled out)</strong></li>\n</ul>",
      "correct_choice_id": 92,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 11,
      "choices": [
        {
          "id": 101,
          "text": "<p><span style=\"font-size:12.0pt;\">Osteosclerosis</span></p>"
        },
        {
          "id": 102,
          "text": "<p><span style=\"font-size:12.0pt;\">Osteophytes</span></p>"
        },
        {
          "id": 103,
          "text": "<p><span style=\"font-size:12.0pt;\">Osteoporotic changes</span></p>"
        },
        {
          "id": 104,
          "text": "<p><span style=\"font-size:12.0pt;\">Periarticular erosions</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 48-year-old lady has had long-standing arthritis of her hands. She has had X-rays done. Which of the following X-ray changes suggests rheumatoid arthritis?</span></p>",
      "unique_key": "DT1197699",
      "question_audio": null,
      "question_video": null,
      "map_id": 1197699,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation</strong>:</p>\n<ul>\n<li>The <strong>hallmark radiological feature of rheumatoid arthritis (RA)</strong> is <strong>periarticular erosions</strong>, which are the result of synovial inflammation invading the bone. Additional features include:\n<ul>\n<li><strong>Periarticular osteopenia</strong> (early stage)</li>\n<li><strong>Symmetrical joint space narrowing</strong></li>\n<li><strong>Soft tissue swelling</strong></li>\n<li><strong>Subchondral bone erosion</strong></li>\n</ul>\n</li>\n<li>Commonly affected joints include:\n<ul>\n<li><strong>Wrists and hands</strong> (MCPs, PIPs)</li>\n<li><strong>Feet</strong>, especially the <strong>lateral aspect of the fifth MTP</strong></li>\n</ul>\n</li>\n<li>These findings help differentiate RA from other arthritides.</li>\n</ul>\n<p><strong>Periarticular erosions</strong></p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/202312075c095353-d749-4b06-875a-2c131a572254.jpg\">\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Osteosclerosis (Option A):</strong> Refers to increased bone density, which is not typical of RA. Seen in conditions like osteoarthritis or sclerotic metastasis.</p>\n<p><strong>Osteophytes (Option B):</strong> Bony outgrowths classically seen in <strong>osteoarthritis</strong>, not RA.</p>\n<p><strong>Osteoporotic changes (Option C):</strong> Generalised osteopenia may occur in RA, but it is <strong>non-specific</strong> and not diagnostic. <strong>Periarticular osteopenia</strong> is more typical.</p>",
      "correct_choice_id": 104,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 12,
      "choices": [
        {
          "id": 111,
          "text": "<p><span style=\"font-size:12.0pt;\">Anti-TNF&alpha; agents</span></p>"
        },
        {
          "id": 112,
          "text": "<p><span style=\"font-size:12.0pt;\">Disease-modifying antirheumatic drugs</span></p>"
        },
        {
          "id": 113,
          "text": "<p><span style=\"font-size:12.0pt;\">Intra-articular corticosteroids</span></p>"
        },
        {
          "id": 114,
          "text": "<p><span style=\"font-size:12.0pt;\">NSAIDs</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 41-year-old woman has a three-month history of progressive pain, swelling and stiffness in both wrists, and the majority of her metacarpophalangeal joints (MCPJs). The symptoms are worse in the morning, and it takes an hour to loosen up her joints. There has been no recent illness, and there is no personal or family history of chronic skin conditions. She drinks alcohol occasionally. On examination, there is synovitis in both wrists and MCPJs. Examination of skin, nails and other joints is normal. These are results of recent blood tests: Haemoglobin 13.1gm/dl (11.5 - 16.5 g/L) WBC 8.2 x 10^9/L (4 - 11 x 10^9/L) Neutrophils 5.1 x 10^9/L (1.5 - 7 x 10^9/L) Platelets 280 x 10^9/L (150 - 400 x 10^9/L)ESR 48 mm/hr (0 - 20 mm/1st hr) Rheumatoid factor: positive (1:256)(<30 k IU/L)Urea, electrolytes and creatinine: Normal.<br>Which among the following will provide immediate symptomatic relief?</span></p>",
      "unique_key": "DT1186780",
      "question_audio": null,
      "question_video": null,
      "map_id": 1186780,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation</strong>:</p>\n<ul>\n<li>The patient presents with typical features of <strong>Rheumatoid Arthritis (RA),</strong> including <strong>morning stiffness &gt;30 minutes</strong>, <strong>symmetric joint involvement (especially MCPJs and wrists), elevated ESR, and positive rheumatoid factor.</strong></li>\n<li><strong>NSAIDs</strong> (Nonsteroidal Anti-inflammatory Drugs) provide <strong>rapid relief</strong> of pain and inflammation, making them the best option for immediate symptomatic improvement.</li>\n<li>However, they do not prevent disease progression.</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Anti-TNF&alpha; agents (Option A):</strong> These biologics are reserved for <strong>moderate-to-severe RA</strong> that is unresponsive to DMARDs. They are not used for initial or immediate symptom control due to time lag for effect and cost considerations.</p>\n<p><strong>Disease-modifying antirheumatic drugs (DMARDs) (Option B):</strong> DMARDs like methotrexate are the <strong>cornerstone for long-term control</strong> of RA, but take <strong>weeks to months</strong> for therapeutic effect. Hence, they are not used for immediate symptom relief.</p>\n<p><strong>Intra-articular corticosteroids (Option C):</strong> While they act quickly, they are used for <strong>localised joint inflammation</strong>, not generalised or bilateral involvement. This patient has multiple joint involvement; thus, systemic NSAIDs are preferred initially.</p>",
      "correct_choice_id": 114,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 13,
      "choices": [
        {
          "id": 121,
          "text": "<p><span style=\"font-size:12.0pt;\">Anti-TNF&alpha; agents</span></p>"
        },
        {
          "id": 122,
          "text": "<p><span style=\"font-size:12.0pt;\">Conventional Disease modifying antirheumatic drugs</span></p>"
        },
        {
          "id": 123,
          "text": "<p><span style=\"font-size:12.0pt;\">Intra-articular corticosteroids</span></p>"
        },
        {
          "id": 124,
          "text": "<p><span style=\"font-size:12.0pt;\">NSAIDs</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">For the patient described in the question above, what will you give for long term management initially?</span></p>",
      "unique_key": "DT1220937",
      "question_audio": null,
      "question_video": null,
      "map_id": 1220937,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p>The cornerstone in the management of RA are DMARDS.</p>\n<p>Conventional DMARDS are the first choice,</p>\n<p>Methotrexate is the DMARD of choice for RA. It can be started either as a monotherapy or with other conventional DMARDS like HCQ, Sulfasalazine.</p>\n<p>Leflunomide is another DMARD that can be used which is equally efficacious as Methotrexate.</p>\n<p>The recent approach is early intensive therapy with combination of DMARDs to minimize disability.</p>\n<p>Reference: Harrison's Principles of Internal Medicine, 21st ed, Ch: 358, Pg: 2761-2764</p>",
      "correct_choice_id": 122,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 14,
      "choices": [
        {
          "id": 131,
          "text": "<p><span style=\"font-size:12.0pt;\">Methotrexate alone</span></p>"
        },
        {
          "id": 132,
          "text": "<p><span style=\"font-size:12.0pt;\">Leflunomide alone</span></p>"
        },
        {
          "id": 133,
          "text": "<p><span style=\"font-size:12.0pt;\">Sulfasalazine with HCQ</span></p>"
        },
        {
          "id": 134,
          "text": "<p><span style=\"font-size:12.0pt;\">Methotrexate with biologicals</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following describes the best prescription for active rheumatoid arthritis in a 45-year-old healthy female without any contraindications?</span></p>",
      "unique_key": "DT1220938",
      "question_audio": null,
      "question_video": null,
      "map_id": 1220938,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation</strong>:</p>\n<ul>\n<li>The current recommendation for active RA is <strong>early, aggressive therapy</strong> to prevent irreversible joint damage.</li>\n<li><strong>Methotrexate</strong> is the cornerstone of treatment in RA and is the base of all combination regimens.</li>\n<li><strong>Combination therapy</strong> should be considered from the start in moderate to severe disease.</li>\n<li>Acceptable combinations include:\n<ul>\n<li>Methotrexate + HCQ + Sulfasalazine (triple therapy)</li>\n<li><strong>Methotrexate + biological agents (e.g., TNF-&alpha; inhibitors)</strong></li>\n<li>Methotrexate + Leflunomide</li>\n</ul>\n</li>\n<li>Therapy should be initiated with Methotrexate and escalated to a combination within 3-6 months if needed.</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Methotrexate alone (Option A):</strong> While Methotrexate is the first-line agent, monotherapy is inadequate in moderate-severe disease.</p>\n<p><strong>Leflunomide alone (Option B):</strong> It is an alternative DMARD, but not superior to MTX, and is not the first-line standalone agent.</p>\n<p><strong>Sulfasalazine with HCQ (Option C):</strong> This dual combination is part of triple therapy but less effective alone; not sufficient for active disease.</p>",
      "correct_choice_id": 134,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 15,
      "choices": [
        {
          "id": 141,
          "text": "<p><span style=\"font-size:12.0pt;\">Anakinra</span></p>"
        },
        {
          "id": 142,
          "text": "<p><span style=\"font-size:12.0pt;\">Tofacitinib</span></p>"
        },
        {
          "id": 143,
          "text": "<p><span style=\"font-size:12.0pt;\">Infliximab</span></p>"
        },
        {
          "id": 144,
          "text": "<p><span style=\"font-size:12.0pt;\">Rituximab</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following is a tsDMARD used in the treatment of RA?</span></p>",
      "unique_key": "DT1220939",
      "question_audio": null,
      "question_video": null,
      "map_id": 1220939,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation</strong>:</p>\n<ul>\n<li><strong>Targeted synthetic DMARDs (tsDMARDs)</strong> are <strong>oral</strong> small molecules that act by inhibiting <strong>Janus Kinases (JAKs)</strong>, which are essential for intracellular cytokine signalling in RA.</li>\n<li>Tofacitinib is a <strong>JAK 1 and JAK 3 inhibitor</strong>, approved for use in RA either alone or in combination with methotrexate.</li>\n<li>Other examples include:\n<ul>\n<li><strong>Baricitinib</strong> - JAK 1 and JAK 2 inhibitor</li>\n<li><strong>Upadacitinib</strong> - JAK 1 inhibitor</li>\n</ul>\n</li>\n<li>Common adverse effects include:\n<ul>\n<li><strong>Neutropenia</strong></li>\n<li><strong>Increased cholesterol</strong></li>\n<li><strong>Elevated serum creatinine and transaminases</strong>&nbsp;</li>\n</ul>\n</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Anakinra (Option A):</strong> Anakinra is an IL-1 receptor antagonist and classified as a biologic DMARD (bDMARD), not a tsDMARD.</p>\n<p><strong>Infliximab (Option C):</strong> Infliximab is a TNF-&alpha; inhibitor and a bDMARD, not a tsDMARD.</p>\n<p><strong>Rituximab (Option D):</strong> Rituximab is a CD20-targeted monoclonal antibody and is classified as a bDMARD.</p>",
      "correct_choice_id": 142,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 16,
      "choices": [
        {
          "id": 151,
          "text": "<p><span style=\"font-size:12.0pt;\">Etanercept</span></p>"
        },
        {
          "id": 152,
          "text": "<p><span style=\"font-size:12.0pt;\">Abatacept</span></p>"
        },
        {
          "id": 153,
          "text": "<p><span style=\"font-size:12.0pt;\">Anakinra</span></p>"
        },
        {
          "id": 154,
          "text": "<p><span style=\"font-size:12.0pt;\">Tocilizumab</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following drugs target TNF?</span></p>",
      "unique_key": "DT1220941",
      "question_audio": null,
      "question_video": null,
      "map_id": 1220941,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>Etanercept is a <strong>TNF-&alpha; inhibitor</strong> used in the treatment of rheumatoid arthritis. It is a <strong>soluble fusion protein</strong> that combines the extracellular ligand-binding portion of the <strong>TNF receptor 2</strong> with the Fc portion of IgG1, allowing it to bind and neutralise circulating TNF-&alpha;.</li>\n<li>Other <strong>TNF-&alpha; inhibitors</strong> include:\n<ul>\n<li><strong>Infliximab</strong></li>\n<li><strong>Adalimumab</strong></li>\n<li><strong>Golimumab</strong></li>\n<li><strong>Certolizumab pegol</strong></li>\n</ul>\n</li>\n<li>These are monoclonal antibodies that directly neutralise TNF-&alpha;, except Etanercept, which is a fusion protein.</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Abatacept (Option B):</strong> It is a selective T-cell co-stimulation modulator that inhibits the CD80/CD86-CD28 interaction.</p>\n<p><strong>Anakinra (Option C):</strong> An IL-1 receptor antagonist; not a TNF inhibitor.</p>\n<p><strong>Tocilizumab (Option D):</strong> A monoclonal antibody against the IL-6 receptor; not related to TNF inhibition.</p>",
      "correct_choice_id": 151,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 17,
      "choices": [
        {
          "id": 161,
          "text": "<p><span style=\"font-size:12.0pt;\">1-iii, 2-i, 3-iv, 4-ii</span></p>"
        },
        {
          "id": 162,
          "text": "<p><span style=\"font-size:12.0pt;\">1-i, 2-ii, 3-iii, 4-iv</span></p>"
        },
        {
          "id": 163,
          "text": "<p><span style=\"font-size:12.0pt;\">1-iii, 2-ii, 3-i, 4-iv</span></p>"
        },
        {
          "id": 164,
          "text": "<p><span style=\"font-size:12.0pt;\">1-ii, 2-iii, 3-i, 4-iv</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Match the following drugs used in the treatment of RA according to the mechanism of action?<br>1. Anakinra - i. Anti IL-6<br>2. Tocilizumab - ii. Co-stimulation inhibitor<br>3. Rituximab - iii. Anti IL-1<br>4. Abatacept - iv. Anti CD 20</span></p>",
      "unique_key": "DT1220942",
      "question_audio": null,
      "question_video": null,
      "map_id": 1220942,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p>The question deals with the various biologics used in RA and their mechanism of action.</p>\n<p>The chief biologicals are the anti TNF&alpha; agents, which are described in the previous question.</p>\n<p>Anakinra is anti IL-1. It has limited use in RA and is used in other autoinflammatory syndromes and Juvenile idiopathic arthritis or Still&rsquo;s Disease.</p>\n<p>Tocilizumab is anti IL6 antibody. Another agent is Sarilumab. IL-6 is the chief cytokine in Ra which leads to activation of osteoclasts.</p>\n<p>Rituximab is anti CD 20 antibody. It is used in seropositive RA, refractory to other biologics.</p>\n<p>Abatacept is a fusion protein consisting of CTLA-4 linked to IgG. It inhibits the co-stimulatory signal for CD4 cells.</p>\n<p>Reference: Harrison's Principles of Internal Medicine, 21st ed, Ch: 358, Pg: 2761</p>",
      "correct_choice_id": 161,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 18,
      "choices": [
        {
          "id": 171,
          "text": "<p><span style=\"font-size:12.0pt;\">Azathioprine</span></p>"
        },
        {
          "id": 172,
          "text": "<p><span style=\"font-size:12.0pt;\">Cyclosporine</span></p>"
        },
        {
          "id": 173,
          "text": "<p><span style=\"font-size:12.0pt;\">Hydroxychloroquine</span></p>"
        },
        {
          "id": 174,
          "text": "<p><span style=\"font-size:12.0pt;\">Methotrexate</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 54-year-old woman on treatment for longstanding rheumatoid arthritis has recently become short of breath on mild exertion and developed a dry cough. Oxygen saturation was found to be 87% on air, and chest x-ray showed a diffuse bilateral interstitial infiltrate. An extensive infection screen was negative, and her symptoms were thought to be drug-induced.<br>Which drug is most likely to have caused this adverse effect?</span></p>",
      "unique_key": "DT1186783",
      "question_audio": null,
      "question_video": null,
      "map_id": 1186783,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation</strong>:</p>\n<ul>\n<li><strong>Methotrexate </strong>is widely used in the management of <strong>rheumatoid arthritis</strong>.</li>\n<li><strong>Pneumonitis </strong>is a potentially <strong>fatal hypersensitivity</strong> <strong>reaction</strong> associated with methotrexate.</li>\n<li>Symptoms are <strong>non-specific </strong>a progressive dyspnoea, cough, fever, hypoxia, tachypnea, and crackles on chest auscultation.</li>\n<li>Chest radiographs reveal <strong>interstitial or alveolar infiltrate</strong>, concentrated within the <strong>lower lung fields.</strong></li>\n<li>Spirometry demonstrates a <strong>restrictive pattern with reduced diffusion capacity</strong>.</li>\n<li>Lung biopsy reveals cellular interstitial infiltrates, granulomas or a diffuse alveolar damage pattern accompanied by perivascular inflammation.</li>\n<li><strong>If suspected, methotrexate should be stopped</strong>, other causes investigated and supportive measures initiated.</li>\n</ul>\n<p>Additional <strong>adverse effects</strong> associated with methotrexate include <strong>hepatic toxicity and neutropenia</strong>. Regular blood tests are done to monitor them.</p>\n<p><strong>Methotrexate</strong> is a <strong>folic acid antagonist</strong>. <strong>Folic acid</strong> should be given <strong>daily</strong> to reduce the incidence of side effects in patients treated with methotrexate.</p>\n<p><strong>Side effects of cytotoxic agents include:</strong></p>\n<p><strong>Azathioprine</strong>: commonly associated with mild bone marrow suppression. Should be used with caution in patients receiving allopurinol due to the risk of life-threatening bone marrow failure. <strong>(Option A)</strong></p>\n<p><strong>Cyclosporine</strong>: common side effects include hirsutism, liver dysfunction, gum hypertrophy and hypertension<strong>. (Option B)</strong></p>\n<p><strong>Hydroxychloroquine</strong> may cause hair loss and 'bull's eye maculopathy'. Visual acuity should be monitored every 6 to 12 months.<strong> (Option C)</strong></p>\n<p><strong>Sulphasalazine</strong>: associated with pancytopenia.</p>",
      "correct_choice_id": 174,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19,
      "choices": [
        {
          "id": 181,
          "text": "<p><span style=\"font-size:12.0pt;\">Tofacitinib</span></p>"
        },
        {
          "id": 182,
          "text": "<p><span style=\"font-size:12.0pt;\">Infliximab</span></p>"
        },
        {
          "id": 183,
          "text": "<p><span style=\"font-size:12.0pt;\">Etanercept </span></p>"
        },
        {
          "id": 184,
          "text": "<p><span style=\"font-size:12.0pt;\">Rituximab</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following drugs used in RA is given orally?</span></p>",
      "unique_key": "DT1220963",
      "question_audio": null,
      "question_video": null,
      "map_id": 1220963,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p>Among the newer agents, JAK inhibitors are the drugs that are given orally among the options.</p>\n<p>Conventional DMARDS are also oral agents.</p>\n<p>Biologicals are all parenteral agents.</p>\n<p>Reference: Harrison's Principles of Internal Medicine, 21st ed, Ch: 358, Pg: 2761-2764</p>",
      "correct_choice_id": 181,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20,
      "choices": [
        {
          "id": 191,
          "text": "<p><span style=\"font-size:12.0pt;\">IV antibiotics, continue methotrexate</span></p>"
        },
        {
          "id": 192,
          "text": "<p><span style=\"font-size:12.0pt;\">IV antibiotics, stop methotrexate, and give folinic acid rescue</span></p>"
        },
        {
          "id": 193,
          "text": "<p><span style=\"font-size:12.0pt;\">IV antibiotics, stop methotrexate temporarily</span></p>"
        },
        {
          "id": 194,
          "text": "<p><span style=\"font-size:12.0pt;\">Oral antibiotics, continue methotrexate</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 57-year-old woman with longstanding well-controlled seropositive Rheumatoid Arthritis, treated with methotrexate (20 mg/week) and folic acid 5 mg/day, presents with cough productive of green phlegm, fever (38.5&deg;C), and severe sore throat. On examination, the BP is 110/70 mmHg, SpO2 is 98% on air. There is an occasional crackle at the right lung base. Chest X-ray is normal. CBC, RFT, and LFTs are also normal. The CRP is 34 mg/L.<br>Which of the following is the most appropriate course of action?</span></p>",
      "unique_key": "DT1186785",
      "question_audio": null,
      "question_video": null,
      "map_id": 1186785,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation</strong>:</p>\n<ul>\n<li>The patient most likely has a <strong>lower respiratory tract infection</strong> (productive cough, fever, localised crackles, elevated CRP).</li>\n<li>In the <strong>setting of acute infection</strong>, immunosuppressants like methotrexate should be <strong>temporarily discontinued</strong> to allow immune clearance of the infection.</li>\n<li>Methotrexate can suppress immune responses, increasing infection risk.</li>\n<li>Continuing it during infection can worsen outcomes.</li>\n<li><strong>IV antibiotics</strong> are justified due to systemic features (fever, high CRP).</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>IV antibiotics, continue methotrexate (Option A):</strong> Continuing methotrexate during active infection is unsafe and may impair immune clearance.</p>\n<p><strong>IV antibiotics, stop methotrexate, and give folinic acid rescue (Option B):</strong> Folinic acid is used in <strong>methotrexate overdose or toxicity</strong>, not routine infection management.</p>\n<p><strong>Oral antibiotics, continue methotrexate (Option D):</strong> While oral antibiotics may suffice in mild infections, this patient has systemic symptoms (fever, raised CRP), requiring the IV route. Methotrexate should still be held.</p>",
      "correct_choice_id": 193,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 21,
      "choices": [
        {
          "id": 201,
          "text": "<p><span style=\"font-size:12.0pt;\">Infliximab</span></p>"
        },
        {
          "id": 202,
          "text": "<p><span style=\"font-size:12.0pt;\">Leflunomide</span></p>"
        },
        {
          "id": 203,
          "text": "<p><span style=\"font-size:12.0pt;\">Prednisolone</span></p>"
        },
        {
          "id": 204,
          "text": "<p><span style=\"font-size:12.0pt;\">Methotrexate</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 54-year-old patient with rheumatoid arthritis has the following full blood count results: Haemoglobin 10.5 g/dL, Platelets 450 x 10^9/L, White Cell Count 8.5 x 10^9/L, MCV 103 fL. Which drug is the likely cause of this?</span></p>",
      "unique_key": "DT1197683",
      "question_audio": null,
      "question_video": null,
      "map_id": 1197683,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation</strong>:</p>\n<ul>\n<li><strong>Methotrexate</strong> is a folate-antagonist DMARD. By inhibiting <strong>dihydrofolate reductase (DHFR)</strong> and downstream folate-dependent reactions, it causes <strong>functional folate deficiency</strong>, leading to:\n<ul>\n<li><strong>Macrocytosis (high MCV) &plusmn; macrocytic anaemia</strong></li>\n<li>Occasional pancytopenia/myelosuppression</li>\n</ul>\n</li>\n<li>These changes are well described in RA patients on chronic methotrexate therapy.</li>\n</ul>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/202312076dd1debe-aea7-4007-afb1-e9a240327c6c.jpg\">\n<p><strong>Explanation of other options</strong></p>\n<p><strong>Infliximab (Option A):</strong> TNF-&alpha; inhibitor; may cause infusion reactions and opportunistic infections but <strong>does not induce macrocytosis</strong>.</p>\n<p><strong>Leflunomide (Option-B):</strong> Can cause cytopenias and hepatotoxicity, yet macrocytosis is <strong>not characteristic</strong>.</p>\n<p><strong>Prednisolone (Option-C):</strong> Glucocorticoids often produce a <strong>neutrophilic leukocytosis</strong>, not macrocytosis.</p>",
      "correct_choice_id": 204,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 22,
      "choices": [
        {
          "id": 211,
          "text": "<p><span style=\"font-size:12.0pt;\">Methotrexate Pneumonitis</span></p>"
        },
        {
          "id": 212,
          "text": "<p><span style=\"font-size:12.0pt;\">RA-associated ILD</span></p>"
        },
        {
          "id": 213,
          "text": "<p><span style=\"font-size:12.0pt;\">Tuberculosis</span></p>"
        },
        {
          "id": 214,
          "text": "<p><span style=\"font-size:12.0pt;\">SARS-CoV-2 pneumonia</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 62-year-old Indian resident has severe rheumatoid arthritis. She has currently on Methotrexate 20 mg weekly for the past 5 months and also has been receiving regular infusions of Infliximab. Her joint disease dramatically improved.<br>She now presents with fevers, cough and weight loss for 20 days. On X-ray, there is evidence of a large left-sided pleural effusion on her CXR.<br>What is the likely diagnosis?</span></p>",
      "unique_key": "DT1197687",
      "question_audio": null,
      "question_video": null,
      "map_id": 1197687,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation</strong>:</p>\n<ul>\n<li>Fever and weight loss of <strong>&gt;2 weeks</strong> indicate a <strong>chronic infectious aetiology</strong>, which is more consistent with <strong>tuberculosis</strong> than an acute process like COVID-19 or drug toxicity.</li>\n<li>Pleural effusion is <strong>unusual for ILD</strong> or methotrexate-induced pneumonitis but common in TB.</li>\n<li>Importantly, <strong>TNF-&alpha; inhibitors like infliximab are known to reactivate latent tuberculosis</strong>.</li>\n<li>Hence, in this immunosuppressed patient, <strong>reactivation of TB</strong> is the most likely cause.</li>\n<li><strong>SARS-CoV-2 pneumonia </strong>causes <strong>bilateral infiltrates</strong>, fever, and dyspnea, but not weight loss over weeks or isolated pleural effusion. <strong>(Option D)</strong></li>\n</ul>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250915c96c7075-12cc-402e-b8ac-d5c42cc370d2.png\">",
      "correct_choice_id": 213,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 23,
      "choices": [
        {
          "id": 221,
          "text": "<p><span style=\"font-size:12.0pt;\">Methotrexate</span></p>"
        },
        {
          "id": 222,
          "text": "<p><span style=\"font-size:12.0pt;\">Azathioprine therapy</span></p>"
        },
        {
          "id": 223,
          "text": "<p><span style=\"font-size:12.0pt;\">Crohn's disease</span></p>"
        },
        {
          "id": 224,
          "text": "<p><span style=\"font-size:12.0pt;\">NSAID therapy</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 51-year-old woman with rheumatoid arthritis was referred with iron deficiency anaemia. She had been taking undisclosed medications for a long time. Endoscopy showed gastritis and antral erosions, small bowel biopsy showing mild villous blunting and apoptotic bodies. Colonoscopy was normal.<br>What could lead to such a presentation for this woman?</span></p>",
      "unique_key": "DT1197695",
      "question_audio": null,
      "question_video": null,
      "map_id": 1197695,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>Chronic use of <strong>NSAIDs</strong> is associated with <strong>upper gastrointestinal mucosal injury</strong>, including <strong>gastritis and antral erosions</strong>, which are known causes of <strong>iron deficiency anaemia</strong>. Additionally:</li>\n<li>NSAIDs exhibit <strong>both analgesic and anti-inflammatory properties</strong> and were once central to RA management.</li>\n<li>However, due to potential adverse effects (GI bleeding, renal dysfunction), they are now considered <strong>adjunctive </strong>therapy<strong>.</strong></li>\n<li><strong>Small bowel injury,</strong> including villous blunting, has also been observed with chronic NSAID use.</li>\n<li>The absence of colonoscopic abnormalities helps rule out colonic causes like Crohn's disease.</li>\n</ul>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\" https://d3d535v34tlady.cloudfront.net/NEETPGMCQ/20231207bdd4ae25-ecee-4efd-81a6-616ac2744434.jpg\">\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Methotrexate (Option A):</strong> Can cause mucosal toxicity, but typically causes <strong>macrocytic anaemia</strong> (due to folate antagonism), not iron deficiency anaemia.</p>\n<p><strong>Azathioprine therapy (Option B):</strong> May cause marrow suppression, but not typically associated with <strong>GI erosions</strong> or iron deficiency anaemia.</p>\n<p><strong>Crohn's disease (Option C):</strong> Can cause anaemia and GI lesions, but would typically show <strong>colonic involvement</strong> or <strong>ileal ulcerations</strong> seen on colonoscopy or imaging, which were not present.<br /> </p>",
      "correct_choice_id": 224,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 24,
      "choices": [
        {
          "id": 231,
          "text": "<p><span style=\"font-size:12.0pt;\">NSAID use and GI bleed</span></p>"
        },
        {
          "id": 232,
          "text": "<p><span style=\"font-size:12.0pt;\">Treatment with celecoxib</span></p>"
        },
        {
          "id": 233,
          "text": "<p><span style=\"font-size:12.0pt;\">Treatment with methotrexate</span></p>"
        },
        {
          "id": 234,
          "text": "<p><span style=\"font-size:12.0pt;\">Anaemia of chronic disease</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 48-year-old woman has severe rheumatoid arthritis. She is currently on ibuprofen and methotrexate. There is no palpable lymphadenopathy and no abdominal masses. Investigations showed that her Hb level is 7.8 g/dl with a MCV of 90, WBC 2.1 x 10^9/l, and platelets 55 x 10^9/l.<br>Retic production index is 0.3%.<br>What is the likely cause of the anaemia?</span></p>",
      "unique_key": "DT1197706",
      "question_audio": null,
      "question_video": null,
      "map_id": 1197706,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation</strong>:</p>\n<ul>\n<li>This patient has <strong>pancytopenia</strong> (anaemia, leukopenia, and thrombocytopenia) with a <strong>low reticulocyte index</strong>, and <strong>no splenomegaly</strong>, suggesting a <strong>bone marrow suppression </strong>aetiology.</li>\n<li><strong>Methotrexate</strong>, a folate antagonist, is a well-known cause of <strong>myelosuppression</strong>, especially at higher doses or in patients with renal dysfunction or folate deficiency.</li>\n<li>This leads to <strong>aplastic anaemia</strong>, with reduced production of all blood cell lines.</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>NSAID use and GI bleed (Option A):</strong> Would cause <strong>isolated iron deficiency anaemia</strong> with <strong>low MCV</strong>, not pancytopenia.</p>\n<p><strong>Treatment with celecoxib (Option B):</strong> Celecoxib is a COX-2 selective NSAID, not typically associated with marrow suppression.</p>\n<p><strong>Anaemia of chronic disease (Option D):</strong> Common in RA, but <strong>does not cause pancytopenia</strong>. Reticulocyte index is typically normal or low-normal, and other lineages (WBC, platelets) are preserved.</p>",
      "correct_choice_id": 233,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 25,
      "choices": [
        {
          "id": 241,
          "text": "<p><span style=\"font-size:12.0pt;\">Ankylosing spondylitis</span></p>"
        },
        {
          "id": 242,
          "text": "<p><span style=\"font-size:12.0pt;\">Syringomyelia</span></p>"
        },
        {
          "id": 243,
          "text": "<p><span style=\"font-size:12.0pt;\">Osteoporosis</span></p>"
        },
        {
          "id": 244,
          "text": "<p><span style=\"font-size:12.0pt;\">Atlanto-axial instability</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 74-year-old woman with longstanding Rheumatoid arthritis has great difficulty walking and comments that both her legs are stiff and 'jumpy'.<br>What is the most likely cause of the presentation?</span></p>",
      "unique_key": "DT1197708",
      "question_audio": null,
      "question_video": null,
      "map_id": 1197708,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation</strong>:</p>\n<ul>\n<li>Spasticity and stiffness in both legs point toward an <strong>upper motor neuron (UMN) </strong>lesion<strong>.</strong></li>\n<li>In rheumatoid arthritis, <strong>cervical spine involvement</strong> is common, and <strong>atlanto-axial instability</strong> at the <strong>C1/C2 level</strong> may cause spinal cord compression.</li>\n<li>The <strong>pyramidal tract</strong> anatomy explains this distribution: sacral fibres are lateral and cervical medial. Hence, <strong>cord compression</strong> initially affects the <strong>lower limbs</strong>, producing bilateral leg symptoms, followed by upper limb involvement.</li>\n<li>Compression from atlanto-axial subluxation is a classic complication of RA due to <strong>ligamentous laxity and erosive changes at the odontoid process</strong>.</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Ankylosing spondylitis (Option A):</strong> Involves the spine but is not typically associated with <strong>atlanto-axial instability</strong> or spastic paraparesis in elderly RA patients.</p>\n<p><strong>Syringomyelia (Option B):</strong> Causes <strong>cape-like sensory loss and dissociated anaesthesia</strong>, not bilateral spastic leg weakness.</p>\n<p><strong>Osteoporosis (option C):</strong> Can cause vertebral fractures, but would not cause <strong>spasticity</strong> or <strong>UMN signs</strong>. Pain would be more prominent.</p>",
      "correct_choice_id": 244,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 26,
      "choices": [
        {
          "id": 251,
          "text": "<p><span style=\"font-size:12.0pt;\">The incidence of RA increases between 25 and 55 years of age, after which it plateaus until the age of 75 and then decreases</span></p>"
        },
        {
          "id": 252,
          "text": "<p><span style=\"font-size:12.0pt;\">The most common pattern of joint involvement is symmetrical and polyarticular.</span></p>"
        },
        {
          "id": 253,
          "text": "<p><span style=\"font-size:12.0pt;\">Flexor tendon tenosynovitis is a frequent hallmark of RA</span></p>"
        },
        {
          "id": 254,
          "text": "<p><span style=\"font-size:12.0pt;\">Macrocytic anaemia is the most common hematologic abnormality in RA</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which is not correct regarding RA?</span></p>",
      "unique_key": "DT1197710",
      "question_audio": null,
      "question_video": null,
      "map_id": 1197710,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation</strong>:</p>\n<ul>\n<li>A <strong>normochromic, normocytic anaemia</strong> often develops in patients with RA and is the <strong>most common hematologic abnormality.</strong></li>\n<li>Macrocytic anaemia may occur in RA due to Methotrexate toxicity.</li>\n<li><strong>Flexor tenosynovitis</strong> can occur in RA. It causes trigger fingers. The most common tendon involved is the Flexor Pollicis Longus.<strong> (Option C)</strong></li>\n<li>The <strong>age of onset of RA</strong> is between <strong>25 to 55 years</strong> of age, after which it <strong>plateaus until the age of 75</strong>, after which it decreases<strong>. (Option A)</strong></li>\n<li>The <strong>most common pattern of involvement is symmetrical, polyarthritis</strong>. <strong>(Option B)</strong></li>\n<li>DIP is usually not involved, but if so, it is often due to OA.</li>\n</ul>",
      "correct_choice_id": 254,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 27,
      "choices": [
        {
          "id": 261,
          "text": "<p><span style=\"font-size:12.0pt;\">2, 3, 4, 5</span></p>"
        },
        {
          "id": 262,
          "text": "<p><span style=\"font-size:12.0pt;\">1, 2, 3, 4</span></p>"
        },
        {
          "id": 263,
          "text": "<p><span style=\"font-size:12.0pt;\">2, 4</span></p>"
        },
        {
          "id": 264,
          "text": "<p><span style=\"font-size:12.0pt;\">2, 4, 5</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which drugs are unsafe and unequivocally contraindicated during pregnancy in a RA patient?<br>1. HCQ<br>2. Methotrexate<br>3. Sulfasalazine<br>4. Leflunomide<br>5. TNF alpha inhibitors<br>6. Glucocorticoids<br>Choose the correct combinations of unsafe drugs.</span></p>",
      "unique_key": "DT1197714",
      "question_audio": null,
      "question_video": null,
      "map_id": 1197714,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>Methotrexate and leflunomide are <strong>contraindicated in pregnancy</strong> due to their well-established <strong>teratogenicity</strong> in both animals and humans. They are <strong>unsafe and must be stopped well before conception</strong>.</li>\n</ul>\n<p>On the other hand:</p>\n<ul>\n<li><strong>Hydroxychloroquine</strong> and <strong>sulfasalazine</strong> are considered <strong>safe</strong> and are commonly used as <strong>first-line options</strong> in pregnancy.</li>\n<li><strong>Low-dose glucocorticoids</strong> (e.g., prednisone) can also be used safely, although long-term or high-dose use carries risks.</li>\n<li><strong>TNF-alpha inhibitors</strong> (biologics) have <strong>increasing evidence of safety</strong>, particularly in the <strong>second and third trimesters</strong>.<br /> </li>\n</ul>\n<p>Hence, only <strong>methotrexate </strong>and<strong> leflunomide</strong> are <strong>unequivocally contraindicated</strong>.</p>",
      "correct_choice_id": 263,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 28,
      "choices": [
        {
          "id": 271,
          "text": "<p><span style=\"font-size:12.0pt;\">Early, aggressive therapy to prevent joint damage and disability</span></p>"
        },
        {
          "id": 272,
          "text": "<p><span style=\"font-size:12.0pt;\">Modify DMARDs only once every 1-2 years, to give them enough time to act</span></p>"
        },
        {
          "id": 273,
          "text": "<p><span style=\"font-size:12.0pt;\">Minimal use of long-term glucocorticoid therapy</span></p>"
        },
        {
          "id": 274,
          "text": "<p><span style=\"font-size:12.0pt;\">Treat either low disease activity or clinical remission.</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which is not a treatment goal in RA?</span></p>",
      "unique_key": "DT1197717",
      "question_audio": null,
      "question_video": null,
      "map_id": 1197717,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>The treatment of RA adheres to the following principles and goals:</p>\n<ul>\n<li><strong>Early, aggressive therapy</strong> to prevent joint damage and disability <strong>(Option A)</strong></li>\n<li><strong>Frequent modification of DMARD</strong> therapy to achieve treatment goals with utilisation of combination therapy where appropriate.</li>\n<li>The usual approach is to begin with methotrexate and rapidly step up (e.g., after<strong> 3-6 months</strong>) to a combination of DMARDs or an anti-TNF or non-TNF biological agent in the absence of an adequate therapeutic response.</li>\n<li>Individualisation of DMARD therapy in an attempt to maximise response and minimise side effects</li>\n<li><strong>Minimal use of long-term glucocorticoid therapy (Option C)</strong></li>\n<li>Achieving, whenever possible, <strong>low disease activity or clinical remission (Option D)</strong></li>\n</ul>",
      "correct_choice_id": 272,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 29,
      "choices": [
        {
          "id": 281,
          "text": "<p><span style=\"font-size:12.0pt;\">Triple therapy</span></p>"
        },
        {
          "id": 282,
          "text": "<p><span style=\"font-size:12.0pt;\">Either A or C</span></p>"
        },
        {
          "id": 283,
          "text": "<p><span style=\"font-size:12.0pt;\">Infliximab</span></p>"
        },
        {
          "id": 284,
          "text": "<p><span style=\"font-size:12.0pt;\">Oral Glucocorticoids</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 52-year-old patient with active rheumatoid arthritis has continued symptoms despite treatment with optimal dose methotrexate. She is having pain in multiple joints. What is the most appropriate next treatment?</span></p>",
      "unique_key": "DT1197720",
      "question_audio": null,
      "question_video": null,
      "map_id": 1197720,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>In patients with active rheumatoid arthritis not controlled with methotrexate alone, <strong>treatment should be intensified</strong>.</li>\n<li>The <strong>preferred next step</strong> in such cases is the addition of a <strong>biologic agent</strong> such as <strong>infliximab</strong> (a TNF-alpha inhibitor).</li>\n<li>According to current guidelines, <strong>early aggressive therapy</strong> is recommended. If there is inadequate response to methotrexate within 3-6 months, <strong>adding a biologic DMARD</strong> is appropriate.</li>\n<li>In contrast, <strong>triple therapy</strong> (methotrexate, hydroxychloroquine, and sulfasalazine) is typically reserved for <strong>milder disease</strong> or as a cost-effective non-biologic option. <strong>(Option A ruled out)</strong></li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Oral glucocorticoids (Option D):</strong> These are <strong>adjuncts for short-term symptom control</strong>, not the next definitive step in disease-modifying therapy.</p>",
      "correct_choice_id": 283,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 30,
      "choices": [
        {
          "id": 291,
          "text": "<p><span style=\"font-size:12.0pt;\">Tender joint count of 2</span></p>"
        },
        {
          "id": 292,
          "text": "<p><span style=\"font-size:12.0pt;\">Swollen joint count of 1</span></p>"
        },
        {
          "id": 293,
          "text": "<p><span style=\"font-size:12.0pt;\">CRP of 10mg/dL</span></p>"
        },
        {
          "id": 294,
          "text": "<p><span style=\"font-size:12.0pt;\">Patient global assessment score of 5</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following represents the targets of treatment in a patient with RA?</span></p>",
      "unique_key": "DT1220979",
      "question_audio": null,
      "question_video": null,
      "map_id": 1220979,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation</strong>:</p>\n<ul>\n<li>The treatment goal in rheumatoid arthritis (RA) is to achieve <strong>low disease activity or remission</strong>, as per the <strong>ACR/EULAR Provisional Definition of Remission</strong>.</li>\n<li>According to the <strong>Boolean-based definition of remission</strong>, a patient must satisfy <strong>all</strong> of the following:\n<ul>\n<li><strong>Tender joint count &le;1 (Option A eluded out)</strong></li>\n<li><strong>Swollen joint count &le;1</strong></li>\n<li><strong>C-reactive protein (CRP) &le;1 mg/dL (Option C ruled out)</strong></li>\n<li><strong>Patient global assessment &le;1</strong> (on a 0-10 scale) <strong>(Option D ruled out)</strong></li>\n</ul>\n</li>\n</ul>",
      "correct_choice_id": 292,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 31,
      "choices": [
        {
          "id": 301,
          "text": "<p><span style=\"font-size:12.0pt;\">Aspirin</span></p>"
        },
        {
          "id": 302,
          "text": "<p><span style=\"font-size:12.0pt;\">Rituximab</span></p>"
        },
        {
          "id": 303,
          "text": "<p><span style=\"font-size:12.0pt;\">Methotrexate</span></p>"
        },
        {
          "id": 304,
          "text": "<p><span style=\"font-size:12.0pt;\">Vincristine</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 42-year-old patient with rheumatoid arthritis was investigated routinely and had the following results:<br>Haemoglobin 11.2 g/dL<br>Platelets 385 x 10^9/L<br>White Cell Count 8.2 x 10^9 /L<br>MCV 110 fL<br>Which drug is she likely to have been on?</span></p>",
      "unique_key": "DT1197730",
      "question_audio": null,
      "question_video": null,
      "map_id": 1197730,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation</strong>:</p>\n<ul>\n<li><strong>Methotrexate</strong> is a commonly used disease-modifying antirheumatic drug (DMARD) in the treatment of rheumatoid arthritis.</li>\n<li>One of its notable adverse effects includes <strong>bone marrow suppression</strong>, particularly when folic acid supplementation is not provided.</li>\n<li>This suppression can result in <strong>pancytopenia or megaloblastic anaemia</strong>, as indicated by the raised <strong>MCV (macrocytic anaemia)</strong> and <strong>low haemoglobin</strong> seen in the patient.</li>\n</ul>\n<h3><strong>Explanation of other options:</strong></h3>\n<p><strong>Aspirin (Option A): </strong>Not associated with macrocytosis or bone marrow suppression; primarily affects platelet function.</p>\n<p><strong>Rituximab (Option B):</strong> Causes B-cell depletion but is not typically associated with macrocytic anaemia.</p>\n<p><strong>Vincristine (Option D):</strong> Can cause neuropathy and leukopenia, but not megaloblastic anaemia or high MCV.</p>",
      "correct_choice_id": 303,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 32,
      "choices": [
        {
          "id": 311,
          "text": "<p><span style=\"font-size:12.0pt;\">Intra-arterial Triamcinolone</span></p>"
        },
        {
          "id": 312,
          "text": "<p><span style=\"font-size:12.0pt;\">Systemic prednisolone</span></p>"
        },
        {
          "id": 313,
          "text": "<p><span style=\"font-size:12.0pt;\">NSAIDS</span></p>"
        },
        {
          "id": 314,
          "text": "<p><span style=\"font-size:12.0pt;\">Increase the dose of Methotrexate</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 50-year-old female with a history of rheumatoid arthritis on a combination of DMARDS now comes with an acute flare in the right knee joint. An aspirate of the joint fluid was done to rule out infection. What is the best modality to treat this?</span></p>",
      "unique_key": "DT1220980",
      "question_audio": null,
      "question_video": null,
      "map_id": 1220980,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation</strong>:</p>\n<ul>\n<li>In patients with rheumatoid arthritis who are already on combination DMARDs and develop an acute flare involving <strong>a single joint</strong>, <strong>intra-articular corticosteroids</strong> (such as <strong>triamcinolone acetate</strong>) are the treatment of choice, <strong>after ruling out infection</strong>.</li>\n<li>This approach provides rapid local symptom relief while minimising systemic steroid exposure.</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Systemic prednisolone (Option B):</strong> Reserved for polyarticular flares or systemic disease activity; not required for isolated monoarticular flare.</p>\n<p><strong>NSAIDs (Option C):</strong> May help with symptoms but are less effective than intra-articular steroids in providing rapid and targeted relief in monoarticular flare.</p>\n<p><strong>Increase the dose of Methotrexate (Option D):</strong> Methotrexate is a slow-acting DMARD, and dose adjustment takes weeks to show effect; not ideal for acute monoarticular flare.</p>",
      "correct_choice_id": 311,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}